CLSA Wire

CLSA Defines 2017 Federal Policy & Advocacy Priorities
Facebook
Twitter
LinkedIn

Feb. 17, 2017

Earlier this month, CLSA’s Board of Directors reviewed and approved the organizations 2017 Federal Policy & Advocacy Agenda, to guide our priority policy and advocacy issues, and related education and outreach opportunities.

In recognition of the current and trending political environment, our federal policy and advocacy work in 2017 will continue to focus on recapturing and reshaping the public narrative away from the cost of new medicines and technologies and toward their value by better communicating the role of biomedical innovation in driving improvements in patient care across our economy.

To respond to current threats, and prepare for upcoming opportunities, like reauthorization of the prescription drug and medical device user fee agreements later this summer, we will continue our aggressive education-focused engagement with legislators, to help them better understand and appreciate our state’s unique biomedical innovation ecosystem, and become familiar with and supportive of the important federal policy issues – such as research funding at NIH and other federal science agencies; FDA regulatory processes; CMS payment and access policies; and tax, trade, and intellectual property policies – that collectively drive our nation’s biomedical innovation sector.

View CLSA’s 2017 Federal Policy Agenda here.

Questions? Please contact Jenny Carey, CLSA’s Vice President of Federal Government Relations and Alliance Development (jcarey@califesciences.org).